Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 229

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 229
---
                    |       — |     |      | 22,383 |
| Stock Options                                               |     |                    |       — |     |      |  7,215 |
| General and administrative stock-based compensation expense |     |                    | 189,348 |     |      | 29,598 |
| Research and development:                                   |     |                    |         |     |      |        |
| RSA awards                                                  |     |                    |  34,107 |     |      |      — |
| RSU awards                                                  |     |                    |       — |     |      |  1,898 |
| Stock Options                                               |     |                    |       — |     |      |    598 |
| Research and development stock-based compensation expense   |     |                    |  34,107 |     |      |  2,496 |
| Total stock-based compensation expense                      |     | $                  | 223,455 |     | $    | 32,094 |

As of March 31, 2025, there was approximately $
of unrecognized stock-based compensation expense related to RSA grants. The unrecognized stock-based compensation expense is expected
to be recognized over a period of year for the RSA grants.

9. Warrants Class C Common Stock Warrants As of March 31, 2025, the Company has 232,360outstanding Class C Common Stock Warrants to purchase up to 485shares of common stock with a exercise price of $ 16.00, which expire on February 14, 2028. The Class C Common Stock Warrants, which were issued in 2023, are treated as a liability due to the alternative cashless exercise for 0.4shares of common stock per warrant. As of March 31, 2025 and December 31, 2024, the fair value of the Class C Common Stock Warrants was $ 829and $ 2,246, respectively, using a Black-Scholes model and Monte-Carlo simulation model as of March 31, 2025 and December 31, 2024, respectively. For the three months ended March 31, 2025 and 2024, the gain of $ 1,417and $ 68,427, respectively, resulting from the change in the fair value of the liability for the unexercised warrants was recorded as a change in fair value of the warrant liability in the accompanying consolidated statements of operations. F-38

Class D